tobramycin has been researched along with posaconazole in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Fosso, MY; Garneau-Tsodikova, S; Shrestha, SK | 1 |
| Fleming, ME; Gordon, WT; Jessie, EM; Khan, M; Malone, DL; Murray, CK; Potter, BK; Rodriguez, CJ; Shackelford, SA; Tribble, DR | 1 |
3 other study(ies) available for tobramycin and posaconazole
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A combination approach to treating fungal infections.
Topics: Antifungal Agents; Candida albicans; Cell Line, Tumor; Cell Survival; Drug Resistance, Fungal; Drug Synergism; Drug Therapy, Combination; Epithelial Cells; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Species Specificity; Tobramycin; Triazoles; Voriconazole | 2015 |
Treatment of Suspected Invasive Fungal Infection in War Wounds.
Topics: Administration, Topical; Afghan Campaign 2001-; Amphotericin B; Antifungal Agents; beta-Cyclodextrins; Debridement; Excipients; Humans; Mycoses; Recurrence; Risk Factors; Tobramycin; Treatment Outcome; Triazoles; Vancomycin; Voriconazole; Wounds and Injuries | 2018 |